Skip to main content

Advertisement

SpringerLink
Log in

Treatment of osteoarthritis with anakinra

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Osteoarthritis (OA) is the most common form of arthritis and one of the leading causes of disability worldwide. The incidence of OA increases with age, and as long-evity increases, it will cause a significant socioeconomic burden. No disease-modifying therapy is available for OA. Recent research has highlighted the role of inflammation in the progression of OA. Interleukin-1 appears to have a significant role in disease progression. Since the interleukin-1 receptor antagonist (IL-1Ra) anakinra has been used successfully in the treatment of the inflammation and bone destruction of rheumatoid arthritis, some have suggested that it may be able to retard the disease progression of OA. This article reviews the data on the use of anakinra in OA treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Woolf AD, Pfleger B: Burden of major musculoskeletal conditions. Bull World Health Organ 2003, 81:646–656.

    PubMed  Google Scholar 

  2. Dennison E, Cooper C: Osteoarthritis: epidemiology and classification. In Rheumatology Two. Edited by Hochberg MC, Silman AJ, Smolen JS, et al. Philadelphia: Elsevier Ltd.; 2003:1781–1791.

    Google Scholar 

  3. Lawrence RC, Helmick CG, Arnett FC, et al.: Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998, 41:778–799.

    Article  PubMed  CAS  Google Scholar 

  4. Wilson MG, Michet CJ Jr, Ilstrup DM, et al.: Idiopathic symptomatic osteoarthritis of the hip and knee: a population-based incidence study. Mayo Clin Proc 1990, 65:1214–1221.

    PubMed  CAS  Google Scholar 

  5. Oliveria SA, Felson DT, Reed JI, et al.: Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum 1995, 38:1134–1141.

    Article  PubMed  CAS  Google Scholar 

  6. Arden N, Nevitt MC: Osteoarthritis: epidemiology. Best Pract Res Clin Rheumatol 2006, 20:3–25.

    Article  PubMed  Google Scholar 

  7. van Saase JL, van Romunde LK, Cats A, et al.: Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 1989, 48:271–280.

    PubMed  Google Scholar 

  8. Goldring MB: The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000, 43:1916–1926.

    Article  PubMed  CAS  Google Scholar 

  9. Myers SL, Brandt KD, Ehlich JW, et al.: Synovial inflammation in patients with early osteo arthritis of the knee. J Rheumatol 1990, 17:1662–1669.

    PubMed  CAS  Google Scholar 

  10. Sukenik S, Henkin J, Zimlichman S, et al.: Serum and synovial fluid levels of serum amyloid A protein and C-reactive protein in inflammatory and noninflammatory arthritis. J Rheumatol 1988, 15:942–945.

    PubMed  CAS  Google Scholar 

  11. Spector TD, Hart DJ, Nandra D, et al.: Low-level increases in serum C-reactive protein are present in early osteoarthritis of the knee and predict progressive disease. Arthritis Rheum 1997, 40:723–727.

    Article  PubMed  CAS  Google Scholar 

  12. Cook JL, Anderson CC, Kreeger JM, et al.: Effects of human recombinant interleukin-1beta on canine articular chondrocytes in three-dimensional culture. Am J Vet Res 2000, 61:766–770.

    Article  PubMed  CAS  Google Scholar 

  13. Arend WP, Malyak M, Guthridge CJ, et al.: Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998, 16:27–55.

    Article  PubMed  CAS  Google Scholar 

  14. Horai R, Saijo S, Tanioka H, et al.: Development of chronic inflammatory arthropathy resembling rheum atoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000, 191:313–320.

    Article  PubMed  CAS  Google Scholar 

  15. Caron JP, Fernandes JC, Martel-Pelletier J, et al.: Chondroprotective effect of intra articular injections of interleukin-1 receptor antagonist in experimental osteo arthritis. Suppression of collagenase-1 expression. Arthritis Rheum 1996, 39:1535–1544.

    Article  PubMed  CAS  Google Scholar 

  16. Fernandes J, Tardif G, Martel-Pelletier J, et al.: In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol 1999, 154:1159–1169.

    PubMed  CAS  Google Scholar 

  17. Pelletier JP, Caron JP, Evans C, et al.: In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997, 40:1012–1019.

    Article  PubMed  CAS  Google Scholar 

  18. Amgen, Inc.: Kineret [package insert]. Thousand Oaks, CA; 2002.

  19. Abramson SB, Amin A: Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage. Rheumatology (Oxford) 2002, 41:972–980.

    Article  CAS  Google Scholar 

  20. Kineret (anakinra): FDA briefing information. US Food and Drug Administration (FDA). 2001.

  21. Bresnihan B, varo-Gracia JM, Cobby M, et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41:2196–2204.

    Article  PubMed  CAS  Google Scholar 

  22. Cohen S, Hurd E, Cush J, et al.: Treatment of rheum atoid arthritis with anakinra, a recombinant hum an interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002, 46:614–624.

    Article  PubMed  CAS  Google Scholar 

  23. Cohen SB, Moreland LW, Cush JJ, et al.: A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheum atoid arthritis treated with background methotrexate. Ann Rheum Dis 2004, 63:1062–1068.

    Article  PubMed  CAS  Google Scholar 

  24. Fleischmann RM, Schechtman J, Bennett R, et al.: Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003, 48:927–934.

    Article  PubMed  CAS  Google Scholar 

  25. Felson DT, Anderson JJ, Boers M, et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995, 38:727–735.

    Article  PubMed  CAS  Google Scholar 

  26. Fries JF, Spitz P, Kraines RG, et al.: Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137–145.

    Article  PubMed  CAS  Google Scholar 

  27. Genant HK, Jiang Y, Peterfy C, et al.: Assessment of rheum atoid arthritis using a modified scoring method on digitized and original radiographs. Arthritis Rheum 1998, 41:1583–1590.

    Article  PubMed  CAS  Google Scholar 

  28. Larsen A, Dale K, Eek M: Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh) 1977, 18:481–491.

    CAS  Google Scholar 

  29. Fleischmann RM, Tesser J, Schiff MH, et al.: Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 2006, 65:1006–1012.

    Article  PubMed  CAS  Google Scholar 

  30. Chevalier X, Giraudeau B, Conrozier T, et al.: Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005, 32:1317–1323.

    PubMed  CAS  Google Scholar 

  31. Kellgren JH, Lawrence JS: Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957, 16:494–502.

    Article  PubMed  CAS  Google Scholar 

  32. O’Quigley J, Pepe M, Fisher L: Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 1990, 46:33–48.

    Article  PubMed  CAS  Google Scholar 

  33. Zohar S, Latouche A, Taconnet M, et al.: Software to compute and conduct sequential Bayesian phase I or II dose-ranging clinical trials with stopping rules. Comput Methods Programs Biomed 2003, 72:117–125.

    Article  PubMed  Google Scholar 

  34. Bellamy N, Goldsmith CH, Buchanan WW, et al.: Prior score availability: observations using the WOMAC osteoarthritis index. Br J Rheumatol 1991, 30:150–151.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 5939 Harry Hines Boulevard, Suite 400, Dallas, Texas, 75235, USA

    Roy Fleischmann MD

Authors
  1. Imran Iqbal MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roy Fleischmann MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roy Fleischmann MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iqbal, I., Fleischmann, R. Treatment of osteoarthritis with anakinra. Curr Rheumatol Rep 9, 31–35 (2007). https://doi.org/10.1007/s11926-007-0019-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0019-9

Keywords

Search

Navigation